Immunotech Biopharm Ltd (6978.HK)

3.240 -0.080 (-2.41%) As of 11:10AM HKT. Market open.

Immunotech Biopharm Ltd

Guosheng Technology Park
8th Floor, Block 1 No.1 Kangding Street Beijing Eco-Tech Dev Area
Beijing
China

https://www.eaal.net

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 211

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Zheng Tan	Executive Chairman	5.04M	N/A	1978
Mr. Hyun Chul Jung	Founder & Chief Strategy Officer	1.98M	N/A	1964
Mr. Ning Yang	CFO & Company Secretary	N/A	N/A	1982
Dr. Yu Zhang	Chief Scientist	N/A	N/A	1964

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in HKD.

Description

Immunotech Biopharm Ltd, a cellular immunotherapy biopharmaceutical company, focuses on the research, development, and commercialization of T cell immunotherapy products for the treatment of cancers in the People's Republic of China. Its core product is EAL, a multi-target cellular immunotherapy product that is in Phase II clinical trials for the prevention of postsurgical recurrence of liver cancer. The company is also conducting pre-clinical and clinical trial studies for EAL to treat lung cancer, glioma, gastric cancer, and colorectal cancer. In addition, it develops 6B11-OCIK injection that is in Phase I clinical trial for ovarian cancer; CAR-T-19 injection product for B-cell acute lymphoblastic leukaemia; RC19D2 for non-hodgkin lymphoma; and TCR-T cell series products to treat solid tumors. Further, the company's pre-clinical products include aT19 to treat acute lymphoblastic leukaemia; CAR-T-43 for T cell leukaemia and T cell lymphoma; CAR-T-22 for B lymphocyte leukaemia; CAR-T-BCMA to treat multiple myeloma; CAR-T-ENX for solid tumors; TCR800 to treat renal cancer; and EBV, CMV specific T cells for EBV/CMV infection. Immunotech Biopharm Ltd was founded in 2006 and is headquartered in Beijing, the People's Republic of China.

Corporate governance

Immunotech Biopharm Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.